CG Oncology/CGON

$30.47

-1.61%
-
1D1W1MYTD1YMAX

About CG Oncology

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Ticker

CGON

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Arthur Kuan

Employees

61

Headquarters

Irvine, United States

CG Oncology Metrics

BasicAdvanced
$1.9B
Market cap
-
P/E ratio
-$1.13
EPS
-
Beta
-
Dividend rate
$1.9B
$50.23
$25.77
636K
57.954
3,462.86
3.281
3.281

What the Analysts think about CG Oncology

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
123.83% upside
High $86.00
Low $50.00
$30.47
Current price
$68.20
Average price target

CG Oncology Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-3,380% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$500K
∞%
Net income
-$17M
4.97%
Profit margin
-3,380%
-∞%

CG Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 24.14%
QuarterlyAnnual
Q1 24
Q2 24
Actual
-$0.36
-
Expected
-$0.29
-$0.35
Surprise
24.14%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for CG Oncology stock?

CG Oncology (CGON) has a market cap of $1.9B as of May 19, 2024.

What is the P/E ratio for CG Oncology stock?

The price to earnings (P/E) ratio for CG Oncology (CGON) stock is 0 as of May 19, 2024.

Does CG Oncology stock pay dividends?

No, CG Oncology (CGON) stock does not pay dividends to its shareholders as of May 19, 2024.

When is the next CG Oncology dividend payment date?

CG Oncology (CGON) stock does not pay dividends to its shareholders.

What is the beta indicator for CG Oncology?

CG Oncology (CGON) does not currently have a Beta indicator.

What is the CG Oncology stock price target?

The target price for CG Oncology (CGON) stock is $68.2, which is 127.48% above the current price of $29.98. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell CG Oncology stock

Buy or sell CG Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing